A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with nonalcoholic fatty liver disease who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on fatty liver disease. Blood tests will also determine how long it takes the body to eliminate LY3849891.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have a body mass index (BMI) ≥25 kilograms per square meter (kg/m²) and ≤50 kg/m²
Participants must have liver fat content ≥10% as determined by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF)
Participants with or without type 2 diabetes mellitus (T2DM). If the participant has T2DM, the hemoglobin A1c (HbA1c)
Male participants must agree to use birth control during the study
Female participants must not be able to get pregnant
Participants Must Not:
Participants must not have known or suspected alcohol abuse (>14 units/week for women and >21 units/week for men) or active substance abuse
Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months
Participants must not have active cancer within the last 5 years
Participants must not have a diagnosis of type 1 diabetes
Participants must not have a history of inflammation of the pancreas
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo